What question did this study set out to answer?

Analyze clinical outcomes and pathologic features of large B-cell lymphoma patients relapsing after CAR T-cell therapy.

December 8, 2025BloodOpen Access

Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy

View Full Paper

Ask AI

Bookmark

Analyze clinical outcomes and pathologic features of large B-cell lymphoma patients relapsing after CAR T-cell therapy.
Retrospective analysis of 146 patients with LBCL after CAR T-cell therapy
Evaluation of treatment outcomes, pathology, and prognosis at relapse
Assessment of CD19 and CD20 expression before and after relapse
48 patients progressed post-CAR T-cell therapy, median overall survival was 9.8 months
1-year overall survival rate was 71% for BsAb-treated patients versus 23% for conventional therapies
Loss of CD20 and/or CD19 was indicated as significant for prognosis and treatment selection

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis reveals CAR T-cell therapy outcomes in large B-cell lymphoma, highlighting impact of bispecific antibodies and tumor progression.

Cite This Study

Takeda et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e583 https://doi.org/10.1182/blood-2025-5440

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals CAR T-cell therapy outcomes in large B-cell lymphoma, highlighting impact of bispecific antibodies and tumor progression.

Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy

Key Points

Discussion

Implication

Cite This Study

Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider